Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma

por Assersohn, L, Norman, A, Cunningham, D, Benepal, T, Ross, P J, Oates, J
Publicado 1999

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

por O'Brien, M E R, Borthwick, A, Rigg, A, Leary, A, Assersohn, L, Last, K, Tan, S, Milan, S, Tait, D, Smith, I E
Publicado 2006

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial

por Kote-Jarai, Z, Powles, TP, Ashley, S, Easton, DF, Assersohn, L, Sodha, N, Dowsett, M, Gusterson, B, Tidy, A, Mitchell, G, Eeles, RA
Publicado 2000

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

por Urruticoechea, A, Archer, C D, Assersohn, L A, Gregory, R K, Verrill, M, Mendes, R, Walsh, G, Smith, I E, Johnston, S R D
Publicado 2005